From PROTAC to inhibitor: Structure-guided discovery of potent and orally bioavailable BET inhibitors
Mladen Koravović(University of Belgrade), Vladimir Savić(University of Belgrade), Huarui Cui(Broad Institute), Martine F. Roussel(St. Jude Children's Research Hospital), Zoran Ranković(St. Jude Children's Research Hospital), Ryan Hiltenbrand(St. Jude Children's Research Hospital), Jeffery M. Klco(St. Jude Children's Research Hospital), Vibhor Mishra(St. Jude Children's Research Hospital), Barbara Jonchère(St. Jude Children's Research Hospital), Timothy R. Stachowski(St. Jude Children's Research Hospital), Leena Paul(St. Jude Children's Research Hospital), William C. K. Pomerantz(University of Minnesota), Sergio C. Chai(St. Jude Children's Research Hospital), Fatemeh Keramatnia(St. Jude Children's Research Hospital), Gordana Tasić(University of Belgrade), Anand Mayasundari(St. Jude Children's Research Hospital), Yong Li(St. Jude Children's Research Hospital), Xiang Fu(St. Jude Children's Research Hospital), Lei Yang(Guangzhou University of Chinese Medicine), Marcus Fischer(St. Jude Children's Research Hospital)
Cited by 9
Related Papers
Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization
|Genes & Development|1998|1.2k
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853
Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
|Proceedings of the National Academy of Sciences|2012|630